News Story: Full Text
Sponsored By
Gleolan for brain tumors
Please Click On The Above Banner For More Details
Braintumor Website


The NovoTTF™-100A System selected as an award finalist based on its innovative design and 1st FDA approved indication for use against recurrent glioblastoma

Posted on: 08/10/2012

Galien Foundation selects NovoTTFTM-100A System as a  finalist for the Prix Galien USA Award   


The NovoTTF™-100A System selected as an award finalist based on its  innovative design and 1st FDA approved indication for use against recurrent  glioblastoma  


New York, NY – August 9, 2012 – The Galien Foundation announced today that  it has selected the NovoTTFT-100A System as a finalist for the prestigious Prix  Galien USA Award in Best Medical Technology. The Prix Galien Awards honor  healthcare companies for outstanding efforts to improve the human condition  through medical research and pharmacology.  The winners are selected by a  preeminent scientific committee that includes several Nobel Laureates.    

“The selection of the NovoTTF-100A System as a finalist for the Prix Galien  USA Awards recognizes the tremendous scientific contributions of Novocure’s  founder and the inventor of the therapy, Yoram Palti, M.D., Ph.D., to the field  of oncology,” commented William F. Doyle, Novocure’s Executive Chairman.  

“Dr. Palti’s insights and leadership enabled the development of an entirely  novel treatment modality for solid tumor cancers and we are pleased that the  Galien Foundation has chosen to consider this innovative product for its annual  award.”  

The Galien Foundation will award the Prix Galien at its annual ceremony on  October 16, 2012 in New York City.  Novocure is one of only two private  companies with products announced as a finalist for the awards.  

About the Galien Foundation and Prix Galien Awards  


The mission of the Galien Foundation is to serve as a vehicle for the open  exchange of ideas that drive science and new innovations.  The Prix Galien  Awards were created to honor medical research and pharmacology for  outstanding efforts to improve the human condition though approval of  innovative treatments and medicines. The winners are selected by a  preeminent scientific and learned committee that included several Nobel  Laureates. Past product award recipients include: Prevnar 13® (Pfizer 2011),  Stelara® (Janssen 2011), Prolia®/XGEVA® (Amgen 2011), Coartem®  (Novartis 2010), RotaTeq® (Merck 2010), xTAG® (Luminex 2010), Gleevec®  (Novartis 2009), Nplate® (Amgen 2009), Promacta® (GSK 2009), Cellsearch®  (Veridex 2009), Isentress® (Merck 2009), Selzentry® (Pfizer 2008), Soliris®  (Alexion 2008), Infuse® (Wyeth 2008), Revlimid® (Celgene 2008), Januvia®  (Merck 2007), Chantix® (Pfizer 2007), Humira® (Abbott 2007) and Gardasil®  (Merck 2007).   

About the NovoTTF™-100A System  


NovoTTF™ Therapy is delivered by the NovoTTF-100A System™, a portable,  non-invasive medical device designed for continuous use throughout the day  by the patient. The device has been shown in in vitro and in vivo studies to  slow and reverse tumor growth by inhibiting mitosis, the process by which cells  divide and replicate. The NovoTTF-100A device, which weighs about six pounds  (three kilograms), creates a low intensity, alternating electric field within the  tumor that exerts physical forces on electrically charged cellular components,  preventing the normal mitotic process and causing cancer cell death prior to  division. In patients with recurrent glioblastoma brain tumors, the device has  been shown to provide patients with efficacy outcomes comparable to active  chemotherapy with fewer side effects and a better quality of life.  The  NovoTTF-100A has received marketing approval in the US and is a CE Marked  device that is cleared for sale in the European Union and Switzerland.  


The US Food and Drug Administration (FDA) approved the NovoTTF-100A  System for use as a treatment for adult patients (22 years of age or older) with  histologically-confirmed glioblastoma multiforme (GBM), following histologically  – or radiologically-confirmed recurrence in the supratentorial region of the  brain after receiving chemotherapy. The device is intended to be used as  monotherapy, and is intended as an alternative to standard medical therapy for  GBM after surgical and radiation options have been exhausted.  

Patients should only use the NovoTTF-100A System under the supervision of a  physician properly trained in use of the device. Full prescribing information is  available at  or by calling toll free 1-855-281-9301.  


About Novocure™  

Novocure™ Limited is a private oncology company pioneering a novel therapy  for solid tumors. Novocure’s worldwide headquarters is located in Jersey.  Novocure’s US operations are based in New York, NY and Portsmouth, NH and  the company’s research center is located in Haifa, Israel. For additional  information about the company, please visit  




Peter Melnyk, Novocure  

(212) 767-7534  



Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557